Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
Portfolio Pulse from
Oruka Therapeutics has begun dosing healthy volunteers in a Phase 1 trial for ORKA-001, a novel antibody targeting IL-23p19. The trial aims to gather pharmacokinetic and safety data by late 2025, with a proof-of-concept study in psoriasis planned for the same period. Initial efficacy data is expected by late 2026.
December 19, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oruka Therapeutics has initiated a Phase 1 trial for ORKA-001, targeting IL-23p19. This marks a significant step in developing treatments for chronic skin diseases, with data expected by late 2025.
The initiation of a Phase 1 trial is a positive development for Oruka Therapeutics, indicating progress in their drug pipeline. The anticipation of pharmacokinetic and safety data by late 2025 and a subsequent proof-of-concept study in psoriasis could drive investor interest and potentially impact stock prices positively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100